Esperion Therapeutics
ESPR
ESPR was delisted on the 10th of July, 2026.
148 hedge funds and large institutions have $426M invested in Esperion Therapeutics in 2022 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 59 increasing their positions, 41 reducing their positions, and 9 closing their positions.
444% more call options, than puts
Call options by funds: $22.5M | Put options by funds: $4.14M
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
44% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 41
21% more capital invested
Capital invested by funds: $352M → $426M (+$73.4M)
9% more funds holding
Funds holding: 136 → 148 (+12)
7.35% more ownership
Funds ownership: 87.8% → 95.15% (+7.3%)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.8M |
| 2 |
Two Sigma Advisers
New York
|
+$7.35M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$5.38M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$5.1M |
| 5 |
Two Sigma Investments
New York
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$6.75M |
| 2 |
ACM
Altium Capital Management
New York
|
-$3.45M |
| 3 |
JP Morgan Chase
New York
|
-$3.29M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$2.5M |
| 5 |
D.E. Shaw & Co
New York
|
-$2.42M |
ESPR Hedge Fund Activity: Q3 2022 in Review
148 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Esperion Therapeutics (ESPR) for Q3 2022, worth a combined $426M — up 21% from $352M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new ESPR positions and 9 closed out — a net gain of 13 holders — while 59 added to existing stakes and 41 trimmed.
The largest buyer was Point72 Asset Management, adding an estimated $11.8M. The largest seller was Millennium Management, cutting an estimated $6.75M.
- 148 institutional investors held Esperion Therapeutics (ESPR) as of Q3 2022, up from 136 in Q2 2022.
- Funds reported $426M of Esperion Therapeutics stock for Q3 2022, up 21% quarter-over-quarter.
- 22 funds opened new Esperion Therapeutics positions in Q3 2022 and 9 closed out, a net change of +13 holders.
- The largest Esperion Therapeutics buyer in Q3 2022 was Point72 Asset Management, an estimated $11.8M added.
- The largest Esperion Therapeutics seller in Q3 2022 was Millennium Management, an estimated $6.75M sold.
Based on aggregated 13F filings for Q3 2022.